According to CRISPR Therapeutics's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 14.7881. At the end of 2023 the company had a P/S ratio of 13.4.
Year | P/S ratio | Change |
---|---|---|
2023 | 13.4 | -99.82% |
2022 | > 1000 | 114832.63% |
2021 | 6.35 | -99.97% |
2020 | > 1000 | 156961.57% |
2019 | 12.8 | -97.3% |
2018 | 474 | 1956.93% |
2017 | 23.1 | -85.24% |
2016 | 156 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
ORIC Pharmaceuticals
ORIC | N/A | N/A | ๐บ๐ธ USA |